Cogent Biosciences, Inc. (NASDAQ:COGT) Financings

Cogent Biosciences, Inc.

Financings

RaiseDate
At-the-market programme of shares
Closed: US$73.6M raised
Use of proceeds: Fund operating expenses and capital expenditures into late 2028, including through potential FDA approvals of bezuclastinib and early commercial launch
Aug 10, 2026
1.625% convertible senior notes due 2031
Update: US$200M · Jefferies +1
Dealers: Jefferies (co-lead), J.P. Morgan (co-lead)
Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes
Nov 11, 2025
Public offering of shares of common stock
Made bigger: US$200M · US$31 a share · J.P. Morgan +5
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Raymond James
Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes
Nov 11, 2025
At-the-market programme of shares of common stock
Closed: US$39M raised
Nov 3, 2025
Public offering of shares of common stock
Closed: US$230M raised · US$9 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Use of proceeds: Development, regulatory and commercial preparation for bezuclastinib and other candidates, its commercial launch, working capital and general corporate purposes
Jul 10, 2025
At-the-market programme of common stock
Closed: US$25M raised
Feb 25, 2025

Read by 6ix AI from the company's releases